CRISPR Therapeutics AG (NASDAQ: CRSP) is 9.73% higher on its value in year-to-date trading and has touched a low of $30.04 and a high of $63.68 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CRSP stock was last observed hovering at around $41.58 in the last trading session, with the day’s gains setting it 1.61%.
Currently trading at $43.19, the stock is 9.91% and 13.95% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.88 million and changing 3.87% at the moment leaves the stock 0.15% off its SMA200. CRSP registered -33.82% loss for a year compared to 6-month loss of -4.87%.
The stock witnessed a 11.40% gain in the last 1 month and extending the period to 3 months gives it a 5.42%, and is 0.58% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.93% over the week and 2.86% over the month.
CRISPR Therapeutics AG (CRSP) has around 393 employees, a market worth around $3.73B and $37.67M in sales. Profit margin for the company is -1023.64%. Distance from 52-week low is 43.77% and -32.18% from its 52-week high. The company has generated returns on investments over the last 12 months (-18.99%).
The EPS is expected to shrink by -25.48% this year.
CRISPR Therapeutics AG (CRSP) Top Institutional Holders
The shares outstanding are 86.36M, and float is at 82.79M with Short Float at 24.81%.
The top institutional shareholder in the company is CAPITAL INTERNATIONAL INVESTORS with over 7.87 million shares valued at $424.8 million. The investor’s holdings represent 9.2619% of the CRSP Shares outstanding. As of 2024-06-30, the second largest holder is ARK INVESTMENT MANAGEMENT LLC with 7.78 million shares valued at $420.12 million to account for 9.1597 of the shares outstanding. The other top investors are SUMITOMO MITSUI TRUST HOLDINGS, INC. which holds 3.15 million shares representing 3.7111% and valued at over $170.21 million, while NIKKO ASSET MANAGEMENT AMERICAS, INC. holds 3.7111 of the shares totaling 3.15 million with a market value of $169.99 million.
CRISPR Therapeutics AG (CRSP) Insider Activity
The most recent transaction is an insider sale by Patel Naimish, the company’s Chief Medical Officer. SEC filings show that Patel Naimish sold 3,932 shares of the company’s common stock on May 29 ’25 at a price of $35.94 per share for a total of $0.14 million. Following the sale, the insider now owns 6068.0 shares.
CRISPR Therapeutics AG disclosed in a document filed with the SEC on Mar 21 ’25 that Kulkarni Samarth (Chief Executive Officer) sold a total of 10,031 shares of the company’s common stock. The trade occurred on Mar 21 ’25 and was made at $41.23 per share for $0.41 million. Following the transaction, the insider now directly holds 0.2 million shares of the CRSP stock.
Still, SEC filings show that on Mar 21 ’25, Bruno Julianne (Chief Operating Officer) disposed off 1,714 shares at an average price of $41.23 for $70668.0. The insider now directly holds 10,544 shares of CRISPR Therapeutics AG (CRSP).
